MauraNDicklerMD

Clinical Trials

• Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Estrogen Receptor (ER)-Negative and Progesterone Receptor (PR)-Negative Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease Start of enrollment: 1999 Apr 01
• Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2002 Dec 01

  Completed

  Phase 2

• Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease Start of enrollment: 1999 Jul 01

  Completed

  Not Applicable

• Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer Start of enrollment: 2006 Jul 01

  Unknown status

  Not Applicable

• Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2007 Mar 20

  Completed

  Not Applicable

• Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 May 15

  Active, not recruiting

  Phase 3

• A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer Start of enrollment: 2009 Feb 01

  Completed

  Phase 1

• Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations Start of enrollment: 2009 Jan 01

  Recruiting

• A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Start of enrollment: 2014 Dec 29

  Terminated

  Phase 1, Phase 2

• BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer Start of enrollment: 2013 May 01

  Completed

  Phase 1

• A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Start of enrollment: 2014 Jun 10

  Completed

  Phase 2

• A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Start of enrollment: 2016 Nov 14

  Active, not recruiting

  Phase 1

• Join now to see all